The vaccine primes neoantigen-specific CD8+ T cells that kill cells presenting the specific neoantigen peptide on HLA class I (e.g., HLA-B) via TCR recognition and perforin/granzyme or Fas–FasL pathways; HLA-B expression alone is not targeted.